1. Park EJ. The quality control of post-authorization study of re-examination in Korea. J Korean Acad Manag Care Pharm. 2015;4(1):1–6.
2. KFDA. Guideline for re-examination on drugs including new drugs. Cheongju: KFDA; 2012.
3. Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1(2):57–60.
4. Faich GA. Postmarketing surveillance: lessons learned. Drug Inf J. 1991;25(4):531–5. https://doi.org/10.1177/009286159102500409.
5. U.S. Food and Drug Administration. What is a Serious Adverse Event? 2020. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event. Accessed 9 Nov 2020.